{
    "organizations": [],
    "uuid": "2ef38c075643bebd7960aca385af4a88f682e61e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-biotime-announces-cash-sale-of-asc/brief-biotime-announces-cash-sale-of-ascendance-biotechnology-idUSFWN1R909S",
    "ord_in_thread": 0,
    "title": "BRIEF-BioTime Announces Cash Sale Of Ascendance Biotechnology",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Biotime Inc:\n* BIOTIME ANNOUNCES CASH SALE OF ASCENDANCE BIOTECHNOLOGY * BIOTIME INC - BIOTIME SUBSIDIARY, AGEX, TO RECEIVE UP TO $3.5 MILLION IN CASH\n* BIOTIME INC - AGEX RECEIVED APPROXIMATELY $3.2 MILLION UPON CLOSE OF ACQUISITION FOR ITS INTEREST IN ASCENDANCE\n* BIOTIME - UPON TERMINATION OF ESCROW, AGEX WILL RECEIVE REMAINDER OF CONSIDERATION SUBJECT TO DEDUCTIONS OF LIABILITIES AND/OR EXPENSES FROM ESCROW Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-27T14:06:00.000+03:00",
    "crawled": "2018-03-27T14:22:17.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "biotime",
        "inc",
        "biotime",
        "announces",
        "cash",
        "sale",
        "ascendance",
        "biotechnology",
        "biotime",
        "inc",
        "biotime",
        "subsidiary",
        "agex",
        "receive",
        "million",
        "cash",
        "biotime",
        "inc",
        "agex",
        "received",
        "approximately",
        "million",
        "upon",
        "close",
        "acquisition",
        "interest",
        "ascendance",
        "biotime",
        "upon",
        "termination",
        "escrow",
        "agex",
        "receive",
        "remainder",
        "consideration",
        "subject",
        "deduction",
        "liability",
        "expense",
        "escrow",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}